statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating Affirmed for CARGO Therapeutics on Promising CAR-T Advancements and Strategic Positioning

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by Chardan Capital analyst, Geulah Livshits. Geulah Livshits has given his...

Contrasting CARGO Therapeutics (NASDAQ:CRGX) and Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE - Get Free Report) and CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two...

CRGX Stock Earnings: Cargo Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CRGX stock results show that Cargo Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 SAN MATEO, Calif...

CARGO Therapeutics Reaches Analyst Target Price

In recent trading, shares of CARGO Therapeutics Inc (CRGX) have crossed above the average analyst 12-month target price of 30.67, changing hands for 32.23/share. When a stock reaches the...

CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...

CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.

Volume	120,593.00
52-Wk High	$33.92
52-Wk Low	$13.14

CRGX CARGO Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals